MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
ConditionLiver Diseases
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Chicago
About this trial
The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients who are already scheduled for an MRI for routine clinical purposes will be evaluated
Disqualifiers
<18 yrs. of age
Trial population
Pts. hospitalized with acute hepatic decompensation Pts. with hepatobiliary neoplasia Pts. undergoing TIPS placement Pts. with chroinic liver disease
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Waitlist Mortality
Death prior to liver transplant or delisting from enrollment in the study
Time frame
Measured up to 10 years out from enrollmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov